Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Retained Earnings (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Retained Earnings for 6 consecutive years, with -$137.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 8.71% to -$137.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$137.0 million, a 8.71% decrease, with the full-year FY2024 number at -$129.5 million, down 6.57% from a year prior.
  • Retained Earnings was -$137.0 million for Q3 2025 at Ensysce Biosciences, down from -$133.2 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$2.9 million in Q1 2021 to a low of -$137.0 million in Q3 2025.
  • A 5-year average of -$105.1 million and a median of -$115.4 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: tumbled 5052.51% in 2021, then fell 5.2% in 2025.
  • Ensysce Biosciences' Retained Earnings stood at -$85.8 million in 2021, then dropped by 29.22% to -$110.9 million in 2022, then fell by 9.58% to -$121.6 million in 2023, then decreased by 6.57% to -$129.5 million in 2024, then fell by 5.72% to -$137.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Retained Earnings are -$137.0 million (Q3 2025), -$133.2 million (Q2 2025), and -$131.5 million (Q1 2025).